Marizyme, Inc. MRZM
Set alert
0.00 USD 0.00 0.00%
At close · Oct 30
0.0081 Day range 0.0081
0.0003 52-week range 0.0081
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.0081
- Prev close
- 0.0003
- Mkt cap
- 39.54K
- Vol
- 1.97K
- Avg vol
- 0
- EPS
- -0.27
- P/E
- 0.00
More statistics
- Low
- 0.0081
- High
- 0.0081
2Y chart
Signals (8)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Mar 28, 2025 | 1 year ago |
| SMA: Bearish | Mar 11, 2025 | 1 year ago |
| RSI: Oversold | Mar 11, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 7, 2025 | 1 year ago |
| SMA: Bullish | Jan 15, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 15, 2025 | 1 year ago |
| RSI: Overbought | Jan 15, 2025 | 1 year ago |
| RSI: Oversold | Dec 27, 2024 | 1 year ago |
News
- Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
- Marizyme CEO Delivers Business Update
- Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™
- U.S. IPO Weekly Recap: The IPO Market's Micro-Cap Run Continues With 2 Small Healthcare Deals
- Marizyme is Pleased to Announce the Appointment of David Barthel as CEO
- Marizyme, Inc. Issues Letter to Shareholders
- Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera
- Marizyme, Inc. Strengthens Senior Management Team with Two Appointments: Roger Schaller EVP, Commercial Operations and Amy Chandler, EVP, Regulatory Affairs and Quality Management Systems
- Marizyme Announces Approval for DuraGraft® in India
- Marizyme Announces the Use of DuraGraft® as the Standard-of-Care in Patients Undergoing Coronary Artery Bypass Surgery (CABG) at Vienna Heart Center North Floridsdorf
Your note
Sign in to keep a note on MRZM — it syncs with the Stock Master app.